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Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7)
Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension
Abstract
Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin–angiotensin
system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymatic product, angiotensin(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension (PH). However, long-term
repetitive delivery of ACE2 or Ang-(1-7) would require enhanced protein stability and ease of
administration to improve patient compliance. Chloroplast expression of therapeutic proteins enables
their bioencapsulation within plant cells to protect against gastric enzymatic degradation and facilitates
long-term storage at room temperature. Besides, fusion to a transmucosal carrier helps effective
systemic absorption from the intestine on oral delivery. We hypothesized that bioencapsulating ACE2 or
Ang-(1-7) fused to the cholera nontoxin B subunit would enable development of an oral delivery system
that is effective in treating PH. PH was induced in male Sprague Dawley rats by monocrotaline
administration. Subset of animals was simultaneously treated with bioencapsulaed ACE2 or Ang-(1-7)
(prevention protocol). In a separate set of experiments, drug treatment was initiated after 2 weeks of PH
induction (reversal protocol). Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) prevented the
development of monocrotaline-induced PH and improved associated cardiopulmonary pathophysiology.
Furthermore, in the reversal protocol, oral ACE2 or Ang-(1-7) treatment significantly arrested disease
progression, along with improvement in right heart function, and decrease in pulmonary vessel wall
thickness. In addition, a combination therapy with ACE2 and Ang-(1-7) augmented the beneficial effects
against monocrotaline-induced lung injury. Our study provides proof-of-concept for a novel low-cost oral
ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary disease therapeutics.
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Abstract
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Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin–
angiotensin system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymatic
product, angiotensin-(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension
(PH). However, long-term repetitive delivery of ACE2 or Ang-(1-7) would require enhanced
protein stability and ease of administration to improve patient compliance. Chloroplast expression
of therapeutic proteins enables their bioencapsulation within plant cells to protect against gastric
enzymatic degradation and facilitates long-term storage at room temperature. Besides, fusion to a
transmucosal carrier helps effective systemic absorption from the intestine on oral delivery. We
hypothesized that bioencapsulating ACE2 or Ang-(1-7) fused to the cholera nontoxin B subunit
would enable development of an oral delivery system that is effective in treating PH. PH was
induced in male Sprague Dawley rats by monocrotaline administration. Subset of animals was
simultaneously treated with bioencapsulaed ACE2 or Ang-(1-7) (prevention protocol). In a
separate set of experiments, drug treatment was initiated after 2 weeks of PH induction (reversal
protocol). Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) prevented the
development of monocrotaline-induced PH and improved associated cardiopulmonary
pathophysiology. Furthermore, in the reversal protocol, oral ACE2 or Ang-(1-7) treatment
significantly arrested disease progression, along with improvement in right heart function, and
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decrease in pulmonary vessel wall thickness. In addition, a combination therapy with ACE2 and
Ang-(1-7) augmented the beneficial effects against monocrotaline-induced lung injury. Our study
provides proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using
transplastomic technology for pulmonary disease therapeutics.

Keywords
chloroplast; molecular farming; plant-made pharmaceuticals; pulmonary hypertension; renin–
angiotensin system
Pulmonary hypertension (PH) is a devastating lung disease characterized by elevated blood
pressure in the pulmonary circulation, which eventually leads to right heart failure and
death.1 Although significant advances have been made in recent years to improve the quality
of life of patients with PH, none of the current treatments are successful in reversing PH or
decreasing mortality. This has led to the realization that novel mechanism-based therapies
must be developed to accomplish this goal.2
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It is well-recognized that activation of the vasodeleterious axis of the renin–angiotensin
system (RAS), comprising of angiotensin-converting enzyme (ACE), angiotensin II, and
angiotensin type I receptor (AT1R), is involved in the development of PH.3,4 However, the
clinical use of ACE inhibitors or AT1R blockers have yielded mixed results, thereby failing
to reach a consensus opinion about their use for PH therapy. Nonetheless, the recent
discovery of a close homolog of ACE, ACE2 has resulted in the reevaluation of the role of
RAS in PH.5,6 ACE2 is widely expressed in the lungs,7 predominantly on the pulmonary
vascular endothelium, and catalyzes the conversion of angiotensin II to Angiotensin-(1-7)
[Ang-(1-7)]. Ang-(1-7) is a vasoactive heptapeptide that mediates its effects by stimulating
the Mas receptor.8 Thus, ACE2–Ang-(1-7)–Mas receptor constitutes the vasoprotective axis
of the RAS, which counterbalances the deleterious actions of the ACE–angiotensin II–AT1R
axis.
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Recent reports indicate that decreased tissue and circulating levels of ACE2 are associated
with lung diseases in humans.9,10 However, restoration of ACE2 through genetic
overexpression, administration of recombinant protein, or use of pharmacological ACE2
activators resulted in cardiopulmonary protective effects against animal models of
pulmonary diseases.11–15 These findings provided compelling evidence for initiating clinical
trials with recombinant ACE2 or Ang-(1-7) in treating pulmonary disorders. Although
clinical trials are currently underway, the cost of manufacturing, protein stability, repetitive
intravenous dosing, and patient compliance pose major impediments in realizing full
therapeutic potential of this therapy. We think that development of a plant-based oral
delivery system will be an ideal approach to overcome these aforementioned challenges and
achieve clinical success.
Therefore, our objective in this study was to develop a low-cost oral delivery system for
administering ACE2 or Ang-(1-7) and test its efficacy in an experimental model of PH. We
took advantage of transplastomic technology that enables chloroplasts to generate high
levels of therapeutic proteins within plant leaves.16–21 This technology presents minimal

Hypertension. Author manuscript; available in PMC 2014 December 01.

Shenoy et al.

Page 3

NIH-PA Author Manuscript

risk of human pathogen or endotoxin contamination, eliminates complex protein purification
steps, and abolishes cold chain and sterile delivery requirements that are commonly
associated with protein therapy.22–24 Efficacy of plant-based pharmaceuticals has been
validated by the fact that Food and Drug Administration has recently approved the use of
taliglucerase alfa (Trade name: Elelyso) in the treatment of Gaucher disease.25 This study
provides evidence for the development of an oral delivery system to administer ACE2 and
Ang-(1-7) using transplastomic technology and demonstrates its efficacy in an established
rat model of monocrotaline-induced PH.

Materials and Methods
The online-only Data Supplement includes detailed descriptions of all the methods and
additional supporting data.

Results
Creation and Characterization of CTB-ACE2 and CTB-Ang-(1-7) Expressed in Plant
Chloroplasts
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The native human ACE2 cDNA and synthetic Ang-(1-7) DNA sequences were cloned into
the chloroplast transformation vector (pLDutr; Figure 1A). For efficient delivery of the
proteins into circulation, a carrier protein, cholera nontoxic B subunit (CTB), was fused to
the N terminal of both therapeutic proteins (Figure 1A), which facilitates their transmucosal
delivery by binding to monosialotetrahexosylganglioside receptors (GM1) present on the
intestinal epithelial cells. Hinge (Gly-Pro-Gly-Pro) and furin cleavage site (Arg-Arg-LysArg) were placed between CTB and therapeutic proteins (Figure 1A) to eliminate steric
hindrance and aid systemic release of these therapeutic proteins after they are internalized
via ligand–receptor complex formation on the surface of epithelial cells. The expression of
the fusion genes was driven by light regulated strong chloroplast psbA promoter, and the
transcripts were stabilized by placing the psbA untranslated region at the 3′ end of the fusion
genes (Figure 1A). To select the chloroplast transformed with the fusion genes,
aminoglycoside-3″-adenylyl-transferase gene (aadA), driven by the chloroplast ribosomal
RNA promoter (Prrn), was incorporated into the expression cassette to confer the
transformants resistance to spectinomycin (Figure 1A). This expression cassette was flanked
by DNA sequences of isoleucyl-tRNA synthetase (trnI) and alanyl-tRNA synthetase (trnA)
genes, identical to the native chloroplast genome at both flanks (Figure 1A). The flanking
sequences serve to facilitate transgene integration into the chloroplast genome (Figure 1A)
via double homologous recombination. Chloroplast transformation vectors expressing the
ACE2 and Ang-(1-7) genes were coated onto gold particles and delivered into chloroplasts
using the biolistic particle delivery system.26 The bombarded plant leaves were then grown
on spectinomycin-containing plant regeneration media. The shoots regenerated from the
media were investigated for the site-specific integration of the transgenes into the
chloroplast genome and homoplasmy of the transgenes (absence of untransformed genomes)
using Southern blot analysis with the radioisotope-labeled probe spanning trnI and trnA
flanking sequences.26 HindIII-digested chloroplast genomic DNA from 3 independent
transplastomic lines for each transplastomic line showed 2 hybridizing fragments at 8.59 and
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3.44 kb for CTB-ACE2 because of an internal Hind III site of ACE2 (Figure 1A) and a
fragment at 9.71 kb for CTB-Ang-(1-7), which confirm the absence of untransformed
chloroplast genomes (Figure 1B and 1C). Thus, stable integration of the transgenes was
confirmed, and the homoplasmic lines were used for further studies. The confirmed
homoplasmic lines were multiplied using another round of antibiotic selection under aseptic
conditions. Then they were cultivated in a controlled greenhouse for increasing biomass.
CTB-ACE2 expression varied between 1.69% and 2.14% of the total leaf proteins (Figure
1D), depending on the harvest time because this transgene is regulated by light via the
chloroplast psbA promoter. Similarly, the expression level of CTB-Ang-(1-7) varied
between 6.0% and 8.7% of total leaf proteins (Figure 1E), at different durations of
illumination, reaching maximum expression at the end of the day. Hence, for performing in
vivo experimental studies, the therapeutic leaf materials were harvested at 6 PM and
powdered in liquid nitrogen.

NIH-PA Author Manuscript
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Both the therapeutic proteins were fused to the transmucosal carrier, CTB. The B subunit
has a single intrasubunit disulfide bond that stabilizes the CTB monomer.25 The monomers
then assemble to form ring-shaped pentameric structure via intersubunit interactions
including hydrogen bonds, salt bridges, and hydrophobic interactions. Upon oral
administration, only the pentameric form of CTB binds to the gut epithelial GM1 receptor
for internalization.27 Hence, we investigated the proper formation of pentameric structure of
the CTB-fused proteins and their binding affinity to GM1 receptor using GM1-ELISA. The
binding affinity between CTB pentamers and the receptor was measured
spectrophotometrically as a function of absorbance at 450 nm. The therapeutic proteins from
the fresh leaf materials showed comparable absorbance to CTB (Figure 1F), confirming that
chloroplasts form disulfide bridges, fold, and assemble these fusion proteins. We also
lyophilized the leaves expressing ACE2 and Ang-(1-7) and evaluated their affinity to the
GM1 receptor (Figure 1F). Lyophilization not only maintained proper folding, disulfide
bond, and pentamer assembly but also facilitated long-term storage at room temperature
(Figure 1F). Furthermore, the Western blot assay performed under nonreducing conditions
without dithiothreitol and boiling showed that there was no monomeric form or cleaved
fragments of CTB-Ang-(1-7) (Figure 1G). In the Western blot image, the major bands for
pentameric assembly of CTB were detected around ≈50 kDa (Figure 1G, arrow head), and
the expected bands for pentameric assembly of CTB-Ang-(1-7) were detected (Figure 1G,
arrow). Therefore, these results confirm that the therapeutic proteins expressed in
chloroplasts exist in an intact and pentameric form.
Oral Feeding of Bioencapsulated ACE2 or Ang-(1-7) Prevents Monocrotaline-Induced PH
Oral gavage of the frozen powdered leaves (500 mg in sterile phosphate-buffered saline)
from untransformed wild type, CTB-ACE2 or CTB-Ang-(1-7) transplastomic plants was
performed twice daily for 4 weeks in monocrotaline-challenged rats. Monocrotaline
injection caused robust elevation in right ventricular systolic pressure (RVSP; Figure 2A)
that was associated with the development of RV hypertrophy (RVH; Figure 2B). In contrast,
monocrotaline animals gavaged with either ACE2 or Ang-(1-7) showed considerable
reduction in RVSP and RVH (Figure 2A and 2B). Furthermore, measurement of
hemodynamic parameters in monocrotaline animals revealed increases in RV end-diastolic
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pressure (153%), +dP/ dt (88%), and −dP/dt (107%). Conversely, treatment with ACE2 or
Ang-(1-7) restored all these parameters to near-control levels (Figure 2C–2E).
Echocardiography of monocrotaline rats revealed an increase in the ratio of RV to left
ventricle end-diastolic area, implying dilation of the right heart (Figure 2F; Figure S1A and
S1B in the online-only Data Supplement), which was accompanied with a decrease in
ejection fraction (EF), measured as a ratio of RV to left ventricle EF (Figure 2G; Figure S1C
and S1D). In addition, the pulsed Doppler blood flow measurement revealed decreased flow
rate in the RV outflow tract (Figure 2H). Furthermore, video of the echocardiography
revealed mal-adaptive structural remodeling in monocrotaline rat hearts as compared with
controls (Movies SI and SII). However, oral delivery of ACE2 or Ang-(1-7) exhibited
improved cardioprotective effects. Both ACE2 and Ang-(1-7) were effective in decreasing
RV dilation (Figure 2F), increasing EF (Figure 2G), and preventing monocrotaline-induced
decrease in RV outflow tract blood flow (Figure 2H). These beneficial effects were
associated with reduced cardiac remodeling as evidenced by echocardiography videos
(Movies SIII and SIV). Concurrently, RV fibrosis and pulmonary vessel wall thickness were
also decreased (Figure 3A and 3B). Oral ACE2 feeding was associated with ~37% increase
in circulating ACE2 activity compared with monocrotaline alone rats (Figure 3C) and a 2fold increase in circulating levels of Ang-(1-7) (Figure S2). Interestingly, ACE2 or Ang(1-7) did not alter the basal systemic blood pressure (control, 120±5; monocrotaline, 123±7;
monocrotaline +ACE2, 118±2; monocrotaline+Ang-(1-7), 116±4; n=5/ experimental group).
Oral ACE2/Ang-(1-7) Treatment Arrests the Progression of Established PH

NIH-PA Author Manuscript

We next tested whether oral feeding of ACE2 or Ang-(1-7) after the initiation of PH could
arrest the disease progression. We observed that 2 weeks of monocrotaline challenge
induces significant elevation in RVSP (>45 mm Hg) compared with controls (Figure S3A).
Hence, for this study, oral therapy was initiated after 2 weeks of monocrotaline challenge,
and the treatment continued for additional 15 days. This regime of treatment with ACE2 or
Ang-(1-7) inhibited further elevation in monocrotaline-induced RVSP and RVH (Figure 4A
and 4B) and was associated with increased circulating levels of Ang-(1-7) (Figure S2).
Improvements in hemodynamic parameters with regard to lowering RV end-diastolic
pressure, decreasing +dP/dt, and reducing −dP/dt were also observed (Figure S3B–S3D). In
addition, ACE2/Ang-(1-7) therapy decreased RV dilation (Figure 4C; Figure Figure S1A
and S1B) and increased RVEF (Figure 4D; Figure S1C and S1D), which was supported by
echocardiography video (Movies SV and SVI). Subsequently, blood flow in the RV outflow
tract was also improved (Figure 4E). Finally, RV fibrosis and pulmonary vessel wall
thickening were significantly attenuated in the ACE2/Ang-(1-7)–treated animals (Figure 4F
and 4G).
Combination Therapy With Oral ACE2 and Ang-(1-7) Feeding Rescues Established PH
Next, we evaluated the effects of a combination therapy with ACE2 and Ang-(1-7), wherein
500 mg or 250 mg each of ACE2 and Ang-(1-7) plant material was combined. Reversal
protocol was followed for this study, wherein the combination therapy was initiated after 2
weeks of monocrotaline challenge, and the treatment continued for the next 15 days. As
expected, we observed better protective effects with the 500 mg combination. This
combination showed 18% more reduction in RVSP and 25% additional decrease in RV/(LV
Hypertension. Author manuscript; available in PMC 2014 December 01.
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+S) ratio compared with the 250 mg combination (Figure 5A and 5B). Similarly, enhanced
beneficial effects of the 500 mg combination were observed for other hemodynamic
parameters such as RV end-diastolic pressure, +dP/dt, and −dP/dt (Figure 5C–5E). Both
doses of the combination therapy were effective in decreasing RV dilatation (Figure 5F;
Figure S1A and S1B) and increasing EF (Figure 5G; Figure S1C and S1D), which was
accompanied by greater RV outflow tract blood flow (Figure 5H). All these observations
were supported by echocardiography video (Movies VII and VIII). Consistent with this were
the improvement in RV fibrosis and pulmonary vessel wall thickness after combination
therapy (Figure 6A and 6B).
Beneficial Effects of ACE2/Ang-(1-7) Oral Therapy Involve Inhibition of Proinflammatory
Cytokines and Autophagy
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We hypothesized that oral delivery of ACE2 or Ang-(1-7) would correct RAS imbalance
and inhibit proinflammatory cytokines. Data in Figure 7 support this hypothesis.
Monocrotaline rats revealed increased pulmonary mRNA levels of ACE and AT1R (Figure
7A and 7D), which resulted in 8-fold and 4-fold increases in the ACE/ACE2 and AT1R/
AT2R ratios, respectively (Figure 7C and 7F). Conversely, mRNA levels of ACE2 and
AT2R were increased, whereas that of AT1R was decreased in the ACE2 or Ang-(1-7)–fed
monocrotaline rats, resulting in decreased ACE/ACE2 and AT1R/AT2R ratios. Furthermore,
monocrotaline-challenged animals showed increased mRNA levels of tumor necrosis factorα (4-fold), transforming growth factor-β (4-fold), and toll-like receptor-4 (5-fold), all of
which were markedly reduced by ACE2 or Ang-(1-7) treatment (Figure 7G–7I). Recent
reports indicate that the autophagic protein degradation pathway is activated in
monocrotaline-challenged animals.28 Accordingly, we observed that the lung LC3B-II
protein, an autophagy marker, was significantly increased in monocrotaline-challenged rats
(Figure 7J). However, ACE2 or Ang-(1-7) decreased LC3B-II levels, implying inhibition of
autophagy. Similar results with respect to RAS modulation, anti-inflammatory properties,
and inhibition of autophagy were observed in the reversal protocol with monotherapy [either
ACE2 or Ang-(1-7)] or combination therapy (Figure 8A–8J).
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The most significant finding of our study is that we have developed a system to generate
human ACE2 and Ang-(1-7) within plant chloroplasts using transplastomic technology,
which when orally administered to rats attenuates PH. Although previous genetic
interventions with ACE2/Ang- (1-7) have demonstrated beneficial effects in animals,11,12
there are several challenges that limit the clinical development of such approaches. The
incidence of PH is increasing among the elderly global population, necessitating affordable
medication for the masses. Although drugs made in plant cells have been approved by the
Food and Drug Administration and are currently marketed,25 targeted gene therapy is still in
the experimental stage and far away from clinical applications. Even if gene therapy is
approved as a valid approach, it would still be accessible to <1% of the global population
because of the limited expertise available in hospitals for gene therapy. In contrast, oral
delivery of plant capsules containing therapeutic proteins is feasible and much affordable.
So, drug delivery is as important as drug discovery, and this study focuses on the
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development of a novel low-cost delivery system for administering therapeutic proteins like
ACE2/Ang-(1-7), which have been found to be effective against experimental models of
lung diseases, but not yet clinically approved. Injectable delivery of ACE2/Ang-(1-7) poses
some unique challenges with respect to cost of manufacturing, protein stability, cold storage,
shelf life, sterile delivery, and requirement of health professionals/hospitals for their
administration. Most of these concerns are easily eliminated by orally delivering therapeutic
proteins bioencapsulated in plant cells. Currently produced injectable protein drugs are not
affordable to more than half of the global population, despite decades of optimization of
their process development. By developing an oral delivery system for administering ACE2
and Ang-(1-7), as reported here, we have made tremendous advancement to move the field
forward and take ACE2/Ang-(1-7) toward translational/clinical research for the treatment of
pulmonary diseases.
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ACE2 and Ang-(1-7) were expressed in plant chloroplasts as fusion proteins with CTB.
Although Ang-(1-7) is not a gene product, a synthetic gene encoding for Ang-(1-7) was used
in this study.29 Chloroplasts are ideal bioreactors for producing human therapeutic proteins.
The total copy number of the transgene per cell is expected to be ≤10 000, resulting in
hyperexpression (≤70% of total leaf protein).16 A single plant cell has ~ 100 chloroplasts,
and each chloroplast has ~100 copies of chloroplast genome. So, ≤10 000 copies of
transgene in each transformed plant cell is observed. This copy number has been quantified
by quantitative polymerase chain reaction in our previous studies.30 However, the most
practical way in the literature to evaluate homoplasmy (transformation of all chloroplast
genomes in each plant cell) is by showing the absence of native untransformed chloroplast
genomes as shown in Figure 1B and 1C. Moreover, this system allows for appropriate
disulfide bond formation, proper protein folding, and assembly.17,18 Also, bio-encapsulation
of proteins within plant cells protects them from gastric degradation. Most importantly,
when fused with trans-mucosal carriers such as CTB, therapeutic proteins are effectively
released into systemic circulation by microbes colonizing the gut, which lyse plant cells,
after CTB-GM1 interaction.18–21 GM1 is also present on the cell membrane of the retina and
nervous system and hence can be targeted by CTB-fused therapeutic proteins, as reported in
our recent study.31,32 Chloroplasts are capable of producing high level expression of foreign
genes. However, the expression levels of ≈93 kDa of ACE2 were below our expectations
compared with Ang-(1-7) (Figure 1C and 1D). The prokaryotic nature of chloroplast is not
well-suited for the expression of eukaryotic human genes because of the bias in codon
preference and usage.33,34 For example, native prokaryotic genes from Bacillus anthracis
and Bacillus thuringiensis were expressed ≤45.3% of the total soluble protein in
chloroplasts.16,35 Small native human genes such as insulin like growth factor-1 (≈7.8
kDa),36 proinsulin (≈12 kDa),16 and interferon-α2b (≈21.5 kDa)37 were expressed in
chloroplasts at high levels. However, larger human native genes like blood clotting factors
were expressed in chloroplasts at lower levels.20 From the analysis of the ACE2 nucleotide
sequence, it was observed that 349 codons of 805 were rare codons (43.5%), which would
readily exhaust the corresponding tRNA pools, leaving relatively abundant tRNAs unused.
Therefore, for clinical development of ACE2, codon optimization and expression in an
edible system (lettuce) should be considered.
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We have used CTB as the transmucosal carrier to facilitate the uptake of ACE2 and Ang(1-7) into circulation. Both CTB fusion proteins are disulfide bonded, form pentamers, and
properly folded, as observed for other CTB fusion proteins.17,18 CTB is an approved
adjuvant38 that has been used in several clinical settings. Administration of CTB-fused
antigen (Behcet’s disease peptide) in humans with autoimmune eye disorders induced
immunologic tolerance by suppressing abnormal T-cell reactivity against the peptide.39
Also, immune suppression to autoantigens (proinsulin and factor IX) linked to CTB has
been observed in animal studies after oral administration.19,20 Likewise, other studies have
shown immune-suppressive effects when CTB was fused to autoimmune or allergic
causative agents.40 The GM1 receptors present on intestinal epithelial cells make CTB the
most appropriate carrier for transporting therapeutic proteins into systemic circulation
because this receptor is widely distributed over the intestinal mucosa41,42 with a rapid
turnover rate.43
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The half-life of native Ang-(1-7) is short.44,45 However, in this study, the stability of Ang(1-7) was found to increase in sera. In plant cells, CTB stabilizes Ang-(1-7) by formation of
pentamers (Figure 1G) and thus confers protection from plant proteases. However, only
monomers are observed in sera after delivery into the sera. Although furin cleavage site
(NH2-R-R-K-R-COOH) should facilitate removal of CTB, efficiency of cleavage depends
on the flanking amino acid sequence of the fused protein.46 Ang-(1-7) fused to CTB did not
provide optimal furin cleavage site because it is not flanked by furin preferred basic amino
acids at N-terminal side and serine–valine at C-terminal side. Therefore, it is anticipated that
furin cleavage will not be rapid or efficient. This offers greater N-terminal protection to
Ang-(1-7) and extends its stability for several hours in the sera compared with injectable
Ang-(1-7). Actually, continued treatment with bioencapsulated Ang-(1-7) showed
significant increases of the circulating levels of the peptide (Figure S2), which suggests that
an oral gavage twice daily of bioencapsulated Ang-(1-7) results in sustained elevated plasma
levels of Ang-(1-7) in the treated animals. Ang-(1-7) concentration in frozen leaf materials
was found to be 584 μg/g, which translates to 292 μg in 500 mg. This dose compares well
with previous studies, wherein 750 to 1000μg/kg of Ang-(1-7) peptide was administered to
rats (≈300 μg per 300 g rat).
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Oral feeding of bioencapsulated ACE2 or Ang-(1-7) prevents the development and, most
importantly, retards the progression of monocrotaline-induced PH. An upregulation of the
deleterious ACE–angiotensin II–AT1R axis and downregulation of the protective ACE2–
Ang-(1-7)–Mas axis contributes to PH pathogenesis.47 Thus, maintaining equilibrium
between these 2 axes is crucial for preserving pulmonary vascular homeostasis. Oral
delivery of ACE2 or Ang-(1-7) increased ACE2/ACE and decreased AT1R/AT2R ratios,
signifying improvement in pulmonary RAS balance. It was interesting to note that the serum
ACE2 activity in monocrotaline animals was decreased compared with controls. This,
however, did not affect the circulating levels of Ang-(1-7), which could possibly be because
of alternate endopeptidase pathways of Ang-(1-7) generation through neprilysin or thimet
oligopeptidase. However, oral ACE2 feeding prevented the decrease in serum ACE2 activity
of monocrotaline animals and was associated with a 2- to 3-fold increase in the circulating
levels of Ang-(1-7) (Figure S2). In fact, ACE2 fed rats exhibited 37% increase in the
enzymatic activity compared with monocrotaline alone animals. Most importantly, this
Hypertension. Author manuscript; available in PMC 2014 December 01.

Shenoy et al.

Page 9

NIH-PA Author Manuscript
NIH-PA Author Manuscript

increase was sufficient to exert beneficial effects against PH pathophysiology. Previous
experimental studies have shown that exogenous administration of recombinant ACE2
increases serum ACE2 activity to exert therapeutic efficacy in several disease models.48–50
Increasing serum ACE2 levels is also clinically significant because abnormally low levels of
serum ACE2 have been associated with PH.10 Surprisingly, pulmonary ACE2 mRNA levels
were increased with oral ACE2 feeding. We speculate this increase to be a positive feed
forward mechanism because similar increases in ACE2 have been reported previously.14,15
Also, AT2R levels were increased with ACE2 treatment, which is consistent with previous
studies showing a protective role of this receptor in cardiopulmonary disease.51
Furthermore, the favorable RAS modulation by ACE2 or Ang-(1-7) was associated with
reduced lung inflammatory cytokines. Proinflammatory cytokines contribute to thickening
of the pulmonary arterioles leading to heightened pulmonary pressure.52 In line with these
findings, we observed marked increases in vessel wall thickness in monocrotalinechallenged animals. However, ACE2 or Ang-(1-7) treatment significantly inhibited medial
wall thickness. The observed effects of ACE2/Ang-(1-7) could be attributed to reduction in
proinflammatory cytokines, as well as direct antiproliferative actions on the vascular smooth
muscle cells, a contention supported by earlier studies.53 Recent studies have implicated
autophagy in PH.26 We observed an increase in LC3B-II, an autophagy marker, in
monocrotaline rats, which was significantly decreased with ACE2 or Ang-(1-7) treatment.
Collectively, aforementioned findings suggest that oral delivery of ACE2 or Ang-(1-7)
corrects a dysregulated pulmonary RAS, reduces inflammation, decreases vascular
remodeling, and inhibits autophagy to exert lung-protective effects. Importantly, ACE2/
Ang-(1-7) treatment did not lower basal systemic blood pressure, which is important
because induction of systemic hypotension can be detrimental in patients with PH. Similar
phenomenon has also been observed in other studies, wherein chronic administration of
Ang-(1-7) fails to decrease systemic blood pressure in a variety of models of
hypertension.54–56 One possibility may be related to pulmonary vasculature being more
sensitive to Ang-(1-7) or that abundant receptors for Ang-(1-7) is present on the pulmonary
vessels. Furthermore, a combination of ACE2 and Ang-(1-7) treatment produced beneficial
effects on the cardiopulmonary system. We observed that the higher dose combination
yielded better effects than the lower dose.
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Of particular interest are the cardioprotective effects of oral ACE2/Ang-(1-7) therapy.
Sustained pressure overload on the right heart induces ventricular remodeling and
dysfunction.57 Echocardiography of monocrotaline rats revealed prominent structural
changes in the heart. The RV assumed a round shape, with a shift in the intraventricular
septum causing RV dilation with reduced EF. In addition, the pulmonary artery flow was
significantly lowered in the monocrotaline group. All these changes were associated with
development of RVH, increased interstitial fibrosis, and cardiac dysfunction. However,
ACE2 or Ang-(1-7) treatment restored normal heart structure, inhibited RV dilatation, and
improved EF. Also, RVH and interstitial fibrosis were significantly reduced, along with
preserved cardiac function. Moreover, the combination therapy with ACE2 and Ang-(1-7)
was found to exert superior cardioprotective effects.
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Evidences have implicated the therapeutic potential of the ACE2/Ang-(1-7) axis in multiple
diseases such as PH, lung-fibrosis, heart failure, renal diseases, and diabetic retinopathy.
This study provides proof-of-concept for a low-cost plant-based oral delivery system for
ACE2 or Ang-(1-7) bioencapsulated in plant chloroplasts. This transplastomic technology
offers the potential to scale-up and generate bulk quantities of therapeutically active ACE2/
Ang-(1-7) toward undertaking translational studies with a simple oral delivery system. In
this direction, we have lyophilized leaves expressing ACE2 or Ang-(1-7), which have
concentrated these therapeutic proteins by ≈20.5- and 14.3-fold, respectively, with no loss
of the binding affinity to GM1 receptor (Figure 1F). The concentration effect is because of
the packaging of more proteins per milligram of lyophilized leaves as a result of elimination
of water by dehydration. So this process does not change the percentage of ACE2/Ang1-7 in
the total leaf protein between fresh and lyophilized plant leaves. This freeze-drying method
is also advantageous in that it reduces the cost associated with protein purification,
eliminates microbial contamination, and facilitates long-term storage of these therapeutic
proteins in capsules at room temperature, which are all important considerations for clinical
development.
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What Is New?
•

This study provides evidence for the first time the development of a low-cost
oral delivery system for the administration of angiotensin-converting enzyme 2
and angiotensin-(1-7) using transplastomic technology that provides impressive
protection against pulmonary hypertension.

What Is Relevant?
•

Angiotensin-converting enzyme 2 and angiotensin-(1-7) have tremendous
therapeutic potential for treating pulmonary hypertension. However, cost of
manufacturing, protein stability, repetitive intravenous dosing, and patient
compliance pose major impediments for successful clinical therapy.
Development of a plant-based oral delivery system will overcome these
challenges to realize full therapeutic potential of these proteins.

Summary
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Oral delivery of angiotensin-converting enzyme 2 or angiotensin-(1-7) bioencapsulated
in plant cells provides protection against pulmonary hypertension and associated
cardiopulmonary pathology.
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Figure 1.
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Characterization, concentration, and evaluation of pentameric structure of cholera nontoxin
B subunit (CTB)-angiotensin-converting enzyme 2 (ACE2) and CTB-angiotensin-(1-7)
[Ang-(1-7)] expressed in plant chloroplasts. A, Schematic representation of CTB-ACE2 and
CTB-Ang-(1-7) gene cassettes and flanking regions. Southern blot analysis of (B) CTBACE2 and (C) CTB-Ang-(1-7) transplastomic lines. HindIII-digested untransformed (UT)
and transformed (lane 1, 2, and 3) genomic DNA was probed with P32-labeled flanking
sequence. Quantification of (D) CTB-ACE2 and (E) CTB-Ang-(1-7) as a percentage of the
total leaf proteins (TLP). F, GM1-binding assay of CTB-ACE2 and CTB-Ang-(1-7). G,
Western blot analysis of CTB-Ang-(1-7) in nonreducing condition without boiling and
dithiothreitol. Lanes 1, 2, and 3: 10, 15, and 20 ng of CTB; total homogenate of CTB-Ang(1-7): 0.2, 0.4, 0.8, and 1.6 μg. The pentameric structures for the CTB alone and the fusion
protein are indicated by arrow head and arrow, respectively. Data shown are mean ± SD of 3
independent experiments. F indicates fresh; L, lyophilized; and BSA, 1% wt/vol.
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Figure 2.
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Oral administration of bioencapsulated angiotensin-converting enzyme 2 (ACE2) or
angiotensin-(1-7) [Ang-(1-7)] prevents monocrotaline (MCT)-induced pulmonary
hypertension. A, Measurement of right ventricular (RV) systolic pressure (RVSP) in normal
controls and MCT-challenged rats that were either untreated or orally fed with wild-type
(WT) leaf material or gavaged with bioencapsulated ACE2/ Ang-(1-7). B, RV hypertrophy,
measured as the ratio of RV to left ventricle (LV) plus interventricular septum (S) weights
[RV/(LV+S)]. Measurement of (C) RV end-diastolic pressure (RVEDP), (D) +dP/dt, and
(E) −dP/ dt. Echocardiography data representing (F) ejection fraction, (G) ratio of the right
to left end-diastolic area, signifying right heart dilation, and (H) the blood flow rate in the
RV outflow tract (RVOT). Data shown are mean ± SEM. ***P<0.001 vs control rats and
#P<0.05 vs untreated or WT leaf-fed MCT rats. n=6 to 8 animals/group.
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Figure 3.
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Oral feeding of bioencapsulated angiotensin-converting enzyme 2 (ACE2) or angiotensin(1-7) [Ang-(1-7)] exerts antifibrotic and antiremodeling effects in the prevention protocol.
A, Interstitial collagen deposition in the right ventricle. B, Staining for α-smooth muscle
actin to quantify medial wall thickness of the pulmonary arteries measuring <50 μm. Scale
bar, 10 μm. C, ACE2 activity was measured in rat sera (10 μL) collected from different
experimental groups Data represents mean ± SEM with *P<0.05 vs other groups, **P<0.01
compared with controls, whereas # representing P<0.05 vs untreated and wild-type (WT)
plant material–fed monocrotaline (MCT) rats as assessed by 1-way ANOVA followed by
Newman–Keuls test. AFU indicates arbitrary fluorescence units.
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Figure 4.

Oral treatment with angiotensin-converting enzyme 2 (ACE2) or angiotensin-(1-7) [Ang(1-7)] arrests disease progression and attenuates cardiopulmonary remodeling. A, Individual
values of the right ventricle systolic pressure (RVSP) from different experimental groups of
the reversal protocol. B, Ratio of RV to left ventricle (LV) plus interventricular septum (S)
weight [RV/(LV+S)] values from individual animals, denoting right heart hypertrophy.
Echocardiography data representing (C) ratio of the right to LV end-diastolic area, (D)
ejection fraction (EF), and (E) the blood flow rate in the RV outflow tract (RVOT) of the
different experimental groups. F, Representative photographs and quantification of
interstitial fibrosis. G, Measurement of vessel wall thickness after α-smooth muscle actin
staining of the pulmonary arteries (<50 μm). Scale bar, 10 μm. Data shown are mean ±
SEM. **P<0.01, ***P<0.001 vs control rats and #P<0.05 vs untreated or wild-type (WT)
leaf-fed monocrotaline (MCT) rats. n=6 to 8 animals/group.
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Figure 5.
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Combination therapy with angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7)
[Ang-(1-7)] rescues established pulmonary hypertension. A, Measurement of right
ventricular systolic pressure (RVSP) in monocrotaline (MCT) rats treated with a
combination of either 500 mg or 250 mg each of ACE2 and Ang-(1-7). B, Data representing
right ventricular hypertrophy as a ratio of RV/(LV+S). Measurement of (C) right ventricular
end-diastolic pressure (RVEDP), (D) +dP/dt, and (E) −dP/ dt from the combination study.
Echocardiography data representing (F) ejection fraction (EF), (G) ratio of the right to left
end-diastolic area, and (H) the blood flow rate in the right ventricular outflow tract (RVOT).
Data shown are mean ± SEM. ***P<0.001 vs control rats and #P<0.05 vs untreated or wildtype (WT) leaf-fed MCT-rats. n=6 to 8 animals/group.
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Figure 6.

Combination of angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) [Ang-(1-7)]
decreases ventricular fibrosis and attenuates pulmonary vascular remodeling. A,
Representative photographs of collagen staining and quantitative analysis of right
ventricular fibrosis after 2 week treatment with combination therapy. B, Measurement of
vessel wall thickness of the pulmonary arteries (<50 μm). Scale bar, 10 μm. Data are
expressed as mean ± SEM; **P<0.01; vs controls and #P<0.05 vs untreated and wild-type
(WT) plant material–fed monocrotaline (MCT) rats. n=5 to 7 animals per experimental
group.
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Figure 7.
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Effects of angiotensin-converting enzyme 2 (ACE2) or angiotensin-(1-7) [Ang-(1-7)]
treatment on the lung renin–angiotensin system, proinflammatory cytokines, and autophagy
(prevention protocol). Relative change in lung mRNA levels of (A) ACE, (B) ACE2, (C)
ACE/ACE2 ratio, (D) angiotensin type 1 receptor (AT1R), (E) angiotensin type 2 receptor
(AT2R), and (F) AT1R/AT2R receptor. Relative mRNA levels of lung proinflammatory
cytokines, G, tumor necrosis factor (TNF)-α, (H) transforming growth factor (TGF)-β, and
(I) toll-like receptor-4 (TLR-4) from the monocrotaline (MCT) study. Autophagy marker,
LC3-II is increased in the lungs of MCT-exposed animals. J, Immunoblot and densitometry
analysis of the lung LC3I/II protein expression. Data are expressed as mean ± SEM.
*P<0.05, **P<0.01, and ***P<0.001 vs control rats. #P<0.05 vs MCT group. WT indicates
wild type.
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Effects of monotherapy, as well as the combination therapy, on the lung renin–angiotensin
system components, proinflammatory cytokines, and autophagy in the reversal protocol.
Data represent relative changes in lung mRNA levels of (A) angiotensin-converting enzyme
(ACE), (B) ACE2, (C) ACE/ ACE2 ratio, (D) angiotensin type 1 receptor (AT1R), (E)
angiotensin type 2 receptor (AT2R), and (F) AT1R/AT2R ratio. Relative mRNA levels of
lung proinflammatory cytokines, (G) tumor necrosis factor (TNF)-α, (H) transforming
growth factor (TGF)-β, and (I) toll-like receptor-4 (TLR-4) from the same study. J,
Immunoblot and densitometry quantification showing lung LC3I/II protein expression. Data
are expressed as mean ± SEM. *P<0.05 and **P<0.01 vs control rats, whereas #P<0.05 vs
monocrotaline (MCT) group. WT indicates wild type.
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